Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review.

导出 LinkOut

翻译打印收藏纠错

作者： Chi,Pan ^[1] ; Tao,Yu ^[2] ; Li,Han ^[2] ; Daxuan,Hao ^[2] ; Ming,Yang ^[2] ; Lin,Li ^[2] ; Laili,Chu ^[2] ; Qingtao,Ni ^[3]

作者单位： Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou. ^[1] Department of Medical Oncology, Xuzhou First People's Hospital, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou. ^[2] Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, China. ^[3]

主题词人类(Humans);肺肿瘤(Lung Neoplasms);小细胞肺癌(Small Cell Lung Carcinoma);吲哚类(Indoles);嘧啶类(Pyrimidines);磺胺类(Sulfonamides)

DOI 10.1097/CAD.0000000000001552

PMID 37948349

发布时间 2024-02-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交